Hormone therapy remains the gold standard for treating menopausal hot flashes: low-dose systemic estrogen (with a progestogen if the uterus is intact) produces the most rapid and robust relief and is recommended for women without contraindications, especially if started within 10 years of menopause onset. Lippincott Journals+1
For women who cannot or choose not to use hormones, several effective nonhormonal options exist. SSRIs/SNRIs (for example, paroxetine or venlafaxine) and gabapentin reduce hot-flash frequency and severity and are well supported by randomized trials and reviews. Cochrane+1 Emerging nonhormonal neurokinin-3 (NK3) receptor antagonists (e.g., fezolinetant and newer agents) target the neural drivers of vasomotor symptoms and offer promising, rapid relief. The Menopause Society Other approaches, including low-dose oxybutynin and procedural options such as stellate-ganglion block, have growing evidence but are generally reserved for refractory cases. saaog.org+1
Recent regulatory updates have also shifted risk communication about menopausal hormone therapy, emphasizing individualized benefit–risk assessment with clinicians. HHS+1
In short: discuss goals, personal risk factors, and preferences with your clinician, as hormone therapy is most effective; nonhormonal pharmacotherapies and new targeted agents provide good alternatives when HT is unsuitable.
Peer-reviewed references
- The North American Menopause Society. The 2023 Nonhormone Therapy Position Statement. Menopause (2023). The Menopause Society
- Cochrane Review: Non-hormonal interventions for reducing hot flushes (2022). Cochrane
- Witten T. et al., Nonhormonal Pharmacotherapies for Vasomotor Symptoms. PMC article (2024). PMC
- Kling JM. Management of the Vasomotor Symptoms of Menopause. Mayo Clinic Proceedings (2024).
